ArticleRisk management and healthcare policy2026
Informing Hospital Formulary Decisions in China: A Multi-Criteria Value Framework for GLP-1 Receptor Agonists.
Article in Risk management and healthcare policy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: GLP-1 receptor agonists have attracted increasing attention due to their dual efficacy in glycemic control and weight reduction. Although several GLP-1 receptor agonists have been included in China's National Reimbursement Drug List, their actual adoption at the hospital level still faces multiple challenges. A well-structured evaluation framework is urgently needed to facilitate their integration into hospital formularies. This study aims to develop a clinically comprehensive evaluation system for GLP-1 receptor agonists in public hospital drug selection, based on multicriteria decision analysis (MCDA). The goal is to provide a systematic and quantifiable tool to support the rational selection and implementation of GLP-1RAs in public hospitals, thereby enhancing the scientific basis of hospital formulary decisions. Patients and Methods: The study integrates the Delphi method and multi-criteria decision analysis (MCDA), utilizing literature review, expert consultations, and questionnaire surveys to select and assign weights to evaluation indicators. Results: A three-tier evaluation system was established, comprising four primary indicators, eight secondary indicators, and seventeen tertiary indicators. Among them, "Clinical Value" had the highest weight (0.5373), followed by "Hospital Admission Demand" (0.1924) and "Hospital Management" (0.1379), while "Economic Value" had the lowest weight (0.1324). At the tertiary level, "Cost-Effectiveness Advantage", "Glycosylated Hemoglobin", "Cardiovascular, Hepatic, and Renal Benefits", "Addressing Unmet Clinical Needs", and "Hypoglycemia Incidence" contributed most to decision-making. Conclusion: This study fills the gap in clinical evaluation research on GLP-1RA drugs in China. The proposed evaluation system provides scientific support for hospital pharmaceutical management, medical insurance inclusion, and drug procurement, promoting value-based hospital drug selection strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.